# Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

> **NCT00086099** · PHASE1,PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 54 (actual)

## Conditions studied

- Leukemia
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Idarubincin and Amufostine (Ethyol)
- **DRUG:** Idarubincin

## Key facts

- **NCT ID:** NCT00086099
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-12
- **Final completion:** 2006-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2009-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086099, "Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00086099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*